New India Drug Price Caps Narrowed To Three Options
This article was originally published in PharmAsia News
Indian price regulators are considering three types of maximum charges for two-thirds of pharmaceuticals not already controlled. One possibility is to cap the trade margin at 300 percent of the manufacturer's price instead of the current 2,900 percent. Another option considered is setting the cap at 50 percent or 70 percent of the leading brand in each category, an option opposed by the National Pharmaceutical Pricing Authority. A third option would set the top price at 15 percent of the printed maximum retail price, 35 percent for retailers. (Click here for more
You may also be interested in...
Hanmi licenses out GLP-1/glucagon receptor dual agonist for NASH to Merck, in a deal worth up to $870m, marking a positive turn for the Korean firm's pipeline after Janssen returned rights last year.
Nomolotus discontinued social media claims that its herbal supplement supports users’ immune systems during the COVID-19 pandemic and customers reviews referencing the virus after the National Advertising Division questioned the statements as misleading.
A PwC analysis finds biopharma aggregate deal value declined 87% during the first half compared to the second half of 2018; deal volume dropped 17%. The pandemic was a cause, but not the only factor.